{
  "report_rows": [
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$108M vs. cons $103.07M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$(1.92) vs. cons $(2.03)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 cash and investments",
      "prediction": "IN-LINE",
      "answer": "pred ~$6.82B vs. cons $6.85B",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total revenue",
      "prediction": "BETTER",
      "answer": "guide ~$2.14B vs. cons $2.09B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Year-end cash and investments",
      "prediction": "UNCHANGED",
      "answer": "guide midpoint ~$4.75B vs. cons $4.75B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "R&D expense",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.00B vs. cons $3.00B (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 6.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FY2026 revenue guide of ~$2.14B versus ~$2.09B consensus and preserved cash guidance should limit estimate cuts; an on-time August 5 flu-vaccine decision can lift 2027 estimates, extending the residual from ~+2.8% on day 1 to ~+6.5% by day 5.",
  "day5_confidence": "LOW"
}